S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS

Bibliographic Details
Published in:	HemaSphere
Main Authors:	Nizar J Bahlis, Katja Weisel, Maria-Victoria Mateos, Hartmut Goldschmidt, Tom Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’souza, Albert Oriol, Laura Rosiñol Dachs, Bhagirathbhai Dholaria, Kalpana Bakshi, Lijuan Kang, Lien Vandenberk, Damiette Smit, Ralph Wäsch, Niels W.C.J. van de Donk, Ajai Chari
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967680.90062.ca

Similar Items

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
by: Lien Vandenberk, et al.
Published: (2023-11-01)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
by: Leo Rasche, et al.
Published: (2023-08-01)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Cyrille Touzeau, et al.
Published: (2023-08-01)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
by: M Mateos, et al.
Published: (2022-04-01)

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
by: Niels W. C. J. van deDonk, et al.
Published: (2025-10-01)

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB
by: N. W. van de Donk, et al.
Published: (2022-06-01)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Surbhi Sidana, et al.
Published: (2023-08-01)

Trimm, Ryan. Heritage and the Legacy of the Past in Contemporary Britain. Routledge. 2018.
by: James Peacock
Published: (2019-01-01)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
by: P Rodriguez-Otero, et al.
Published: (2022-04-01)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
by: Niels W.C.J. van de Donk, et al.
Published: (2023-08-01)

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

Talquetamab in multiple myeloma
by: Lawrence Liu, et al.
Published: (2023-10-01)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Hermann Einsele, et al.
Published: (2023-08-01)

REAL-WORLD (RW) TREATMENT PATTERNS AND OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH AT LEAST ONE PRIOR THERAPY IN TURKEY
by: Ozgur Pektas, et al.
Published: (2023-10-01)

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
by: Nizar J Bahlis, et al.
Published: (2023-08-01)

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY
by: Vania Hungria, et al.
Published: (2023-08-01)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
by: M Mateos, et al.
Published: (2023-05-01)

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1
by: N. W. C. J van de Donk, et al.
Published: (2022-04-01)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)
by: M.C. Minnema, et al.
Published: (2023-05-01)

Adébáyọ̀ Fálétí Dará Ilẹ
by: Adedotun Ogundeji (Àtàrí Àjààkú)
Published: (2021-12-01)

Talquetamab: A promising immunotherapy for multiple myeloma
by: Amna Tariq, et al.
Published: (2023-10-01)

P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
by: Margaret Macro, et al.
Published: (2023-08-01)

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
by: M. Macro, et al.
Published: (2022-06-01)

The Dara'ang and The Art of Becoming Governed
by: Gwen Marie McCaw, et al.
Published: (2022-07-01)

Historical Interactions of Dārā Shukūh with Hinduism
by: Alireza Ebrahim
Published: (2019-12-01)

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
by: Gang An, et al.
Published: (2025-10-01)

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation
by: Rebecca W. Silbermann, et al.
Published: (2023-08-01)

S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: J. L. Kaufman, et al.
Published: (2022-06-01)

The requirement of Dara's rule according to Emirate or principle
by: Reza Elhami, et al.
Published: (2025-01-01)

An Ampulla of Saint Menas from Dara (Anastasiopolis)
by: Hüseyin Metin
Published: (2025-01-01)

Inclining doubt in the rule of avoidance of punishment (darā’)
by: Mahmoud Pourbafrani, et al.
Published: (2020-03-01)

Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma
by: Mark Forsberg, et al.
Published: (2024-02-01)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
by: A. Suvannasankha, et al.
Published: (2022-06-01)

TRATAMENTO DE INFILTRAÇÃO MENÍNGEA POR MIELOMA MÚLTIPLO COM TALQUETAMAB
by: F Pedott, et al.
Published: (2024-10-01)

Psychological Reflections in the Paintings of the Artist Dara Muhammad Ali
by: Tawana Yahya khudhur, et al.
Published: (2024-08-01)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Sagar Lonial, et al.
Published: (2023-08-01)

1700-tal
by: Gunnar Broberg, et al.
Published: (2008-01-01)

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
by: Jan H. Frenking, et al.
Published: (2025-04-01)

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
by: Syed Naqvi, et al.
Published: (2024-08-01)